Together, these examples show that what antibody repertoires “see” is determined by the interplay between viral glycoprotein structure, B cell precursor availability, somatic evolution, and population‐level immunoglobulin diversity.
Abstract
Human infection with or vaccination against influenza A virus has been one of the most informative systems for understanding how human antibody repertoires recognize viral glycoproteins. Decades of antibody isolation, repertoire sequencing, lineage tracing, serology, viral antigenic evolution, and structural biology have shown that antibody recognition is not simply a matter of “which epitope is targeted.” Instead, each surface on the viral hemagglutinin (HA) presents a distinct structural problem for the immune system. Repeated exposures through infection and vaccination coupled with continuous antigenic drift generate complex immune histories and reveal which viral surfaces evolve under antibody pressure. Structural studies have transformed the field by showing how antibody repertoires solve epitope‐specific recognition problems. Some epitopes, such as the HA central stem, recruit highly stereotyped genetic and structural solutions. Others, such as the receptor‐binding site, can be approached by genetically diverse antibodies that converge on common structural solutions of receptor mimicry. Additional epitopes, including the lateral patch, anchor, head interface, and head‐stem junction, reveal intermediate patterns of repertoire constraint. Together, these examples show that what antibody repertoires “see” is determined by the interplay between viral glycoprotein structure, B cell precursor availability, somatic evolution, and population‐level immunoglobulin diversity.
ABSTRACT Influenza B viruses contribute substantially to seasonal disease burden; however, the structural basis by which antibodies recognize the major glycoprotein hemagglutinin (HA) and mediate antiviral activity remains incompletely defined. Influenza B virus used to circulate as two antigenically distinct lineages,...
D. Bhavsar, Alesandro Civljak, Bruno Bonnettaz et al.· Journal of Virology· 0 citations
Influenza A virus continues to pose pandemic threats, as demonstrated by the recent global spread of highly pathogenic H5N1 strains. Consequently, the development and characterization of vaccines targeting zoonotic influenza subtypes have become a major focus of the field. In this study, we characterize two broadly rea...
Guthrie L. Stroh, Hui-Bin Lv, Chun-Ke Chen et al.· bioRxiv· 0 citations
Vaccination with real-world complex antigens often elicits a hierarchical immune response to different epitopes. This immunodominance is a major obstacle in vaccine design because nonprotective epitopes often divert the immune response away from protective epitopes. We posited that B cell epitope avidity (i.e., total m...
Mauricio V. Padilla, Nicole G Weidner, Layne Pruitt et al.· Science Translational Medici...· 3 citations
ABSTRACT The lateral patch epitope of the H1 hemagglutinin (HA) was a dominant target of antibodies following exposure to the 2009 pandemic H1N1 virus. However, the conservation and mechanisms of antigenic drift in the lateral patch remain unresolved. Here, we used lateral patch-specific monoclonal antibodies (mAbs) to...
Jordan I. Lemus-Reyes, Monica L. Fernández-Quintero, Edgardo Ayala et al.· Journal of Virology· 0 citations
Broadly neutralizing antibodies (bNAbs) provide insights for developing universal influenza vaccines through their ability to neutralize diverse viral strains. However, designing antigens that reliably elicit bNAb responses remains challenging due to the difficulty in targeting conserved epitopes with a single antigen....
H. Itou, Kaori Sano, A. Ainai et al.· Protein Science· 0 citations
Influenza viruses are a constant threat to human health. Current vaccines often confer low to moderate protection against infection with seasonal viruses and little‐to‐no protection against pandemic viruses. Improved vaccines are needed. These vaccines will need to reliably elicit antibodies to conserved sites that are...
Kevin R. McCarthy· Immunological Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.